Our Vision
We aspire to become global leaders in analytical and diagnostic devices and to sustain high growth through innovation.
Ultimately, we aim to democratise access to state-of-the-art biological analyses by dramatically reducing costs.
We have a strong track record in medical technology development, including physics, chemistry, electronics, microfluidics and related manufacturing methods.
The company is currently raising funds to support the commercialization of its first products that target the life science and related sectors research needs. This will set the stage for its commercialization of its technology in innovative point of care applications such as diagnostics and personalized treatments.
blood, saliva and urine with unprecedented resolution, speed and reproducibility in a miniature fluidic chip.
Our disposable chips coupled with our high performance readers will enable the cost-effective screening of the general population for disease biomarkers that normally require state-of-the-art expensive analytical protocols.
For example, we perform analysis of cancer related assays in less than 5 minutes at a cost per analysis that is a fraction of popular ELISA analyses that take 10 hours or more to perform.
In DNA sequencing, a specially designed DNA chip, allows for diagnostic sequencing with long reads, next generation speed at a fifth of the cost compared to popular Next Generation Sequencers.
The cost effectiveness, ease of use, accuracy and long read lengths of the GMD technology platform makes the technology suitable for life science research, diagnostics and point of care applications.
and diagnostic devices as well as in their use for analysing biomarkers in cancer, CVD and chronic illness.
This will assist healthcare institutions and payers to help patients and manage costs, by diagnosing disease early and by providing personalised therapies.
Our cost effective but powerful technology will tip the balance from post-diagnosis therapies, to wide population screening strategies, that will help many more people. In addition it will open up the routine use of complex biological analysis at the point of care, enhancing treatment outcomes affordably.
We aspire to become global leaders in analytical and diagnostic devices and to sustain high growth through innovation.
Ultimately, we aim to democratise access to state-of-the-art biological analyses by dramatically reducing costs.
At Genetic Microdevices, we have very high aspirations to capture a significant fraction of the Medtech and Diagnostic markets.
The company is led by Dimitrios Sideris who is founder and CEO. Our Board of Directors consists of experienced, highly skilled individuals who have excelled in their field and have shown strong & lasting commitment to the vision of the company.
The commercial and technical management team is currently being enriched with world-wide leaders who forge confidence in achieving our ambitious goals.
Unit 6, Princess Mews
Horace Road
Kingston upon Thames
Surrey, KT1 2SZ – UK
United Kingdom
GMD USA Inc
Call: +1 (646) 394-9098
Leave us a message
Unit 6, Princess Mews,
Horace Road
Kingston upon Thames,
Surrey, KT1 2SZ
UK
8 The Green
Suite B
City Of Dover
Kent County
Delaware 19901
United States of America